SEARCH

SEARCH BY CITATION

References

  • Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P et al. (1994). Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 8: 12371244.
  • Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M et al. (2009). Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 14: 75.
  • Albini A, Indraccolo S, Noonan DM, Pfeffer U (2010). Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis 27: 419439.
  • Alexander A, Smith PF, Rosengren RJ (2009). Cannabinoids in the treatment of cancer. Cancer Lett 285: 612.
  • Alexander CM, Howard EW, Bissell MJ, Werb Z (1996). Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 135: 16691677.
  • Alexander SPH, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1S324.
  • Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F et al. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med DOI: 10.1007/s00109-011-0856-x [Epub ahead of print].
  • Bagnato A, Spinella F, Rosanò L (2008). The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473484.
  • Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J et al. (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827832.
  • Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L et al. (2002). Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16: 267269.
  • Benelli R, Albini A, Noonan D (2003). Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. In: Cassatella MA (ed.). The Neutrophil: An Emerging Regulator of Inflammatory and Immune Response. Karger: Basel, pp. 167181.
  • Bertaux B, Hornebeck W, Eisen AZ, Dubertret L (1991). Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97: 679685.
  • Blázquez C, Casanova ML, Planas A, Gómez del Pulgar T, Villanueva C, Fernández-Aceñero MJ et al. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529531.
  • Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 56175623.
  • Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G et al. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20: 26332635.
  • Cantelmo AR, Cammarota R, Noonan DM, Focaccetti C, Comoglio PM, Prat M et al. (2010). Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene 29: 52865298.
  • Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW et al. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111: 4350.
  • Cattaneo MG, Chini B, Vicentini LM (2008). Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 153: 728736.
  • Cattaneo MG, Lucci G, Vicentini LM (2009). Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 315: 32103219.
  • Chung AS, Lee J, Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505514.
  • Curry FR, Glass CA (2006). TRP channels and the regulation of vascular permeability: new insights from the lung microvasculature. Circ Res 99: 915917.
  • De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 14791494.
  • Fassina G, Venè R, Morini M, Minghelli S, Benelli R, Noonan DM et al. (2004). Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 10: 48654873.
  • Ferrari N, Tosetti F, De Flora S, Donatelli F, Noonan DM, Albini A (2010). Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr Drug Targets 12: 19091924.
  • Fiorio Pla A, Avanzato D, Munaron L, Ambudkar IS (2012). Ion channels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as molecular targets. Am J Physiol Cell Physiol 302: C9C15.
  • Flygare J, Sander B (2008). The endocannabinoid system in cancer-potential therapeutic target? Semin Cancer Biol 18: 176189.
  • Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 2731.
  • Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273286.
  • Freimuth N, Ramer R, Hinz B (2010). Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332: 336344.
  • Gertsch J, Pertwee RG, Di Marzo V (2010). Phytocannabinoids beyond the Cannabis plant – do they exist? Br J Pharmacol 160: 523529.
  • Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R et al. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 8792.
  • Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E et al. (2005). Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer 103: 16761684.
  • Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58: 933943.
  • Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A et al. (1998). In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 20022010.
  • Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG (2001). Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. Am J Pathol 158: 12071215.
  • Guindon J, Hohmann AG (2011). The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 14471463.
  • Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 2932.
  • Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 15771579.
  • Jaffe EA, Nachman RL, Becker CG, Minick CR (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunological criteria. J Clin Invest 52: 27452756.
  • Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 1413614141.
  • Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H et al. (2005). Matrix metalloproteinases in carcinoma of unknown primary. Cancer 104: 22822287.
  • Kesisis G, Broxterman H, Giaccone G (2007). Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 13: 27952809.
  • Korff T, Augustin HG (1998). Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143: 13411352.
  • Korff T, Augustin HG (1999). Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112: 32493258.
  • Kwan HY, Huang Y, Yao X (2007). TRP channels in endothelial function and dysfunction. Biochim Biophys Acta 1772: 907914.
  • Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). J Cell Sci 115: 34273428.
  • Lai Y, Shen Y, Liu XH, Zhang Y, Zeng Y, Liu YF (2011). Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-kinase-Rac1/RhoA pathway. Int J Biol Sci 7: 782791.
  • Li G, Fridman R, Kim HR (1999). Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59: 62676275.
  • Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 13751387.
  • Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A et al. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835840.
  • Lorusso G, Vannini N, Sogno I, Generoso L, Garbisa S, Noonan DM et al. (2009). Mechanisms of hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer 45: 14741484.
  • Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J et al. (2010). Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180189.
  • Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838845.
  • Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D (2006). The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 63: 20572066.
  • Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E et al. (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104: 10911100.
  • McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6: 29212927.
  • McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J et al. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129: 3747.
  • McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S et al. (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627634.
  • McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 70: 897908.
  • McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 15731576.
  • Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M et al. (1997). Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76: 531536.
  • Mo FM, Offertáler L, Kunos G (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489: 2127.
  • Nasser JA, Falavigna A, Ferraz F, Duigou G, Bruce J (2006). Transcription analysis of TIMP-1 and NM23-H1 genes in glioma cell invasion. Arq Neuropsiquiatr 64: 774780.
  • Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A (2008). Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27: 3140.
  • Noonan DM, Ventura A, Bruno A, Pagani A, Albini A (2011a). The angiogenic switch: role of immune cells. In: Wang E, Marincola F (eds). Immunologic Signatures of Rejection. Springer: New York, pp. 5775.
  • Noonan DM, Sogno I, Albini A (2011b). Plants and plant-derived products as cancer chemopreventive agents. In: Bagetta G, Cosentino M, Corasaniti MT, Sakurada S (eds). Herbal Medicines: Development and Validation of Plant-Derived Medicines for Human Health. CRC Press Inc: Boca Raton, FL, pp. 285306.
  • O'Sullivan SE, Kendall DA (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215: 611616.
  • O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612: 6168.
  • Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M (2007). Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 211: 495503.
  • Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG et al. (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117: 55415550.
  • Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 17711773.
  • Preet A, Ganju RK, Groopman JE (2008). Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27: 339346.
  • Qiu J, Wang G, Hu J, Peng Q, Zheng Y (2011). Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin. Mol Cell Biochem 357: 125133.
  • Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ et al. (2011). Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 13: R18.
  • Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M et al. (2010). Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS ONE 5: e12458.
  • Ramer R, Merkord J, Rohde H, Hinz B (2010a). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 79: 955966.
  • Ramer R, Rohde A, Merkord J, Rohde H, Hinz B (2010b). Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res 27: 21622174.
  • Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997). High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3: 16231628.
  • Russo EB (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 13441364.
  • Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG et al. (2004). Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10: 22892298.
  • Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10: 11611172.
  • Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E et al. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10: 90103.
  • Ulisse S, Baldini E, Sorrenti S, D'Armiento M (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9: 3271.
  • Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 10321036.
  • Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518521.
  • Yokoyama Y, Xin B, Shigeto T, Mizunuma H (2011). Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol 137: 12191228.
  • Yoshiji J, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M et al. (1998). Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75: 8187.
  • Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG (1995). Elevated tissue inhibitor of metalloproteinase I RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899906.
  • Zhuge X, Murayama T, Arai H, Yamauchi R, Tanaka M, Shimaoka T et al. (2005). CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun 331: 12951300.